FDA Grants Approval for Dapsone ANDA218335 by Macleods Pharmaceuticals
The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 218335 for Dapsone submitted by Macleods Pharmaceuticals.
Company
Macleods Pharmaceuticals
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The FDA's approval of Macleods Pharmaceuticals' ANDA for Dapsone signifies a shift in the competitive landscape for this antimicrobial. This could lead to pricing pressures and necessitate strategic adjustments from existing branded manufacturers to maintain market share.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timelines and pricing strategies of Macleods Pharmaceuticals for Dapsone.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.